Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

BACKGROUND: Oncogenic K-Ras signaling highly relies on the canonical Ras/MEK/ERK pathway to contribute to pancreatic cancer progression. However, numerous efforts of MEK inhibitors have failed to provide an optimal antitumor effect for pancreatic cancer in practice. The aim of the present work was t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chao, Min-Wu, Chang, Li-Hsun, Tu, Huang-Ju, Chang, Chao-Di, Lai, Mei-Jung, Chen, Yi-Ying, Liou, Jing-Ping, Teng, Che-Ming, Pan, Shiow-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540419/
https://www.ncbi.nlm.nih.gov/pubmed/31142371
http://dx.doi.org/10.1186/s13148-019-0681-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540419/
https://www.ncbi.nlm.nih.gov/pubmed/31142371
http://dx.doi.org/10.1186/s13148-019-0681-6

Ejemplares similares